The core element of our ADC platform is our patented hydrophilic polysarcosine, PSARlink technology. It is the cornerstone of the design of our ADCs as it overcomes the intrinsic hydrophobicity of most cytotoxic payloads.
Our ADC platform:
- dramatically increases the overall hydrophilicity of the conjugate
- allows to reach DAR up to 16
- overcomes plasma stability issues for an optimal action against tumor cells